Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429405 | 1.00 | LMNA (0.37) | LMNAALDH1A1PTGS1PTGS2MCOLN3 | |
| SCHEMBL5424514 | 0.93 | TAS1R3 (0.38) | LMNAALDH1A1PTGS1PTGS2SYK | |
| SCHEMBL5416203 | 0.93 | TAS1R3 (0.38) | LMNAALDH1A1PTGS1PTGS2SYK | |
| SCHEMBL5413840 | 0.91 | HTT (0.33) | LMNAALDH1A1KDM1A | |
| SCHEMBL5424758 | 0.91 | HTT (0.33) | LMNAALDH1A1KDM1A | |
| Hexamethylbenzene SCHEMBL5415733 | 0.90 | HCRTR2 (0.33) | LMNAPTGS1PTGS2HDAC4 | |
| Hexamethylbenzene SCHEMBL5430986 | 0.90 | HCRTR2 (0.33) | LMNAPTGS1PTGS2HDAC4 | |
| O-Xylene SCHEMBL5423466 | 0.89 | KAT2B (0.36) | LMNAALDH1A1PTGS1PTGS2KAT2B | |
| O-Xylene SCHEMBL5421596 | 0.89 | KAT2B (0.36) | LMNAALDH1A1PTGS1PTGS2KAT2B | |
| P-Xylene SCHEMBL5420017 | 0.89 | TSHR (0.40) | ALDH1A1PTGS1PTGS2MCOLN3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268250-B2 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20040176616-A1 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176616-A1 | Process for producing optically active compound | OSTC, NPEPPS, PPOX | LMNA 4034/4885ALDH1A1 3566/4885PTGS1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.